Blockchain Registration Transaction Record

Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. for Q4 2024, Highlighting Breakthrough Technology in Obesity and Oncology

Stonegate Capital Partners updates coverage on Bio-Path Holdings, Inc. for Q4 2024, demonstrating the DNAbilize® platform's potential in obesity and oncology. Learn about the company's breakthrough technology, ongoing clinical trials, strategic partnerships, and strong IP position.

This news matters as it showcases the innovative potential of Bio-Path's DNAbilize® platform in revolutionizing cancer treatment and addressing metabolic diseases like obesity. Investors, healthcare professionals, and individuals interested in medical advancements should take note of the company's progress in clinical trials and the strategic partnerships driving its success.